Suresh Muthukumaraswamy

Suresh Muthukumaraswamy (Ph.D.) is a Principal Investigator in the Centre for Brain Research and the Auckland Neuropsychopharmacology Research Group. His main research interests are in understanding how therapies alter brain activity and in developing methodologies to measure these changes in both healthy individuals and patient groups. His previous studies investigated a range of compounds including hallucinogens (ketamine, LSD, psilocybin), anesthetics, anti-epileptics, and GABA-enhancers using a wide range of neuroimaging techniques. His current work investigates ketamine and midazolam using simultaneous EEG/fMRI recordings, and the effects of ketamine, scopolamine, and rTMS in depression.